{"organizations": [], "uuid": "a095648133a99921c93fc1ea16e354af88b3c004", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ema-validates-bristol-myers-type-i/brief-ema-validates-bristol-myers-type-ii-variation-application-for-opdivo-plus-yervoy-combination-for-treatment-of-first-line-metastatic-non-small-cell-lung-cancer-idUSFWN1SA0TR", "country": "US", "domain_rank": 408, "title": "BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T15:41:00.000+03:00", "replies_count": 0, "uuid": "a095648133a99921c93fc1ea16e354af88b3c004"}, "author": "", "url": "https://www.reuters.com/article/brief-ema-validates-bristol-myers-type-i/brief-ema-validates-bristol-myers-type-ii-variation-application-for-opdivo-plus-yervoy-combination-for-treatment-of-first-line-metastatic-non-small-cell-lung-cancer-idUSFWN1SA0TR", "ord_in_thread": 0, "title": "BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "nsclc", "sentiment": "none"}, {"name": "squibb co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News May 3, 2018 / 12:42 PM / in 11 minutes BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer Reuters Staff 1 Min Read\nMay 3 (Reuters) - Bristol-Myers Squibb Co:\n* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBBâ€™S TYPE II VARIATION APPLICATION FOR OPDIVO PLUS YERVOY COMBINATION FOR TREATMENT OF FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)\n* BRISTOL-MYERS SQUIBB CO - APPLICATION IS BASED ON DATA FROM PART 1 OF CHECKMATE -227, A GLOBAL PHASE 3 STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-03T15:41:00.000+03:00", "crawled": "2018-05-03T16:00:28.042+03:00", "highlightTitle": ""}